Trials / Not Yet Recruiting
Not Yet RecruitingNCT07415226
Glucose-lowering Drugs as an Adjunct to Insulin Therapy in Chinese Patients With Type 1 Diabetes
Effectiveness and Safety of Glucose-lowering Drugs as an Adjunct to Insulin Therapy in Chinese Patients With Type 1 Diabetes: a Retrospective, Observational Study
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To assess the real-world impact of glucose-lowering drugs (GLDs) as an adjunct to insulin in Chinese patients with type 1 diabetes (T1DM). Does glucose-lowering drugs (GLDs) as an adjunct to insulin improve clinical outcomes in Chinese patients with type 1 diabetes (T1DM) when used long-term in real-world practice?
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GLD+insulin group | The glucose-lowering drugs included in the analysis were metformin, acarbose and DPP-4i alone or in combination with other agents. |
Timeline
- Start date
- 2026-05-01
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
- First posted
- 2026-02-17
- Last updated
- 2026-02-17
Source: ClinicalTrials.gov record NCT07415226. Inclusion in this directory is not an endorsement.